Skip to contentS
Sonoma Pharmaceuticals, Inc.
S
SNOASonoma Pharmaceuticals, Inc. Q1 2024 · 10-Q
Revenue$3.43M$3.43M−14.0% vs Q1 2023 Net Income-$1.42M-$1.42MN/M vs Q1 2023 EPS Diluted-$0.29-$0.29N/M vs Q1 2023 Gross Profit$1,204,000−26.9% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Sonoma Pharmaceuticals, Inc. · CIK 1367083 · Engraved from SEC EDGAR
Operating Cash Flow-$215,000N/M Free Cash Flowderived-$232,000N/M Margins · derivedGross margin35.1%−6.2 pt vs Q1 2023
Operating margin-36.2%−14.7 pt vs Q1 2023
Net margin-41.4%−19.1 pt vs Q1 2023
ended Jun 30, 2023 · filed Aug 10, 2023 · 41 d after period end